Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 111

1.

Role of consolidation/maintenance therapy in multiple myeloma.

Palumbo A, Mina R, Cerrato C, Cavallo F.

Clin Lymphoma Myeloma Leuk. 2013 Sep;13 Suppl 2:S349-54. doi: 10.1016/j.clml.2013.05.009. Review.

PMID:
24290220
[PubMed - indexed for MEDLINE]
2.

Part II: role of maintenance therapy in transplant-ineligible patients.

Palumbo A, Mina R.

J Natl Compr Canc Netw. 2013 Jan 1;11(1):43-9. Review.

PMID:
23307980
[PubMed - indexed for MEDLINE]
3.

Management of older patients with multiple myeloma.

Gay F, Palumbo A.

Blood Rev. 2011 Mar;25(2):65-73. doi: 10.1016/j.blre.2010.10.003. Epub 2011 Feb 4. Review.

PMID:
21295387
[PubMed - indexed for MEDLINE]
4.

(Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.

Wang A, Duan Q, Liu X, Ding K, Han Y, Zhu W, Cai X, Wu J, Sun Z.

Ann Hematol. 2012 Nov;91(11):1779-84. doi: 10.1007/s00277-012-1520-4. Epub 2012 Jul 7.

PMID:
22773209
[PubMed - indexed for MEDLINE]
5.

Role of consolidation therapy in transplant eligible multiple myeloma patients.

Cavo M, Brioli A, Tacchetti P, Zannetti BA, Mancuso K, Zamagni E.

Semin Oncol. 2013 Oct;40(5):610-7. doi: 10.1053/j.seminoncol.2013.07.001. Review.

PMID:
24135406
[PubMed - indexed for MEDLINE]
6.

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.

Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M, Di Raimondo F, Crippa C, Zamagni E, Palumbo A, Offidani M, Corradini P, Narni F, Spadano A, Pescosta N, Deliliers GL, Ledda A, Cellini C, Caravita T, Tosi P, Baccarani M; GIMEMA Italian Myeloma Network.

Lancet. 2010 Dec 18;376(9758):2075-85. doi: 10.1016/S0140-6736(10)61424-9. Epub 2010 Dec 9. Erratum in: Lancet. 2011 Nov 26;378(9806):1846.

PMID:
21146205
[PubMed - indexed for MEDLINE]
7.

Shifts in the therapeutic paradigm for patients newly diagnosed with multiple myeloma: maintenance therapy and overall survival.

Palumbo A, Attal M, Roussel M.

Clin Cancer Res. 2011 Mar 15;17(6):1253-63. doi: 10.1158/1078-0432.CCR-10-1925. Review.

PMID:
21411441
[PubMed - indexed for MEDLINE]
Free Article
8.

Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated results.

Gay F, Magarotto V, Crippa C, Pescosta N, Guglielmelli T, Cavallo F, Pezzatti S, Ferrari S, Liberati AM, Oliva S, Patriarca F, Offidani M, Omedé P, Montefusco V, Petrucci MT, Giuliani N, Passera R, Pietrantuono G, Boccadoro M, Corradini P, Palumbo A.

Blood. 2013 Aug 22;122(8):1376-83. doi: 10.1182/blood-2013-02-483073. Epub 2013 Jun 17. Erratum in: Blood. 2014 Jun 12;123(24):3843.

PMID:
23775712
[PubMed - indexed for MEDLINE]
Free Article
9.

How to treat elderly patients with multiple myeloma: combination of therapy or sequencing.

Palumbo A, Gay F.

Hematology Am Soc Hematol Educ Program. 2009:566-77. doi: 10.1182/asheducation-2009.1.566. Review.

PMID:
20008241
[PubMed - indexed for MEDLINE]
Free Article
10.

Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.

Palumbo A, Gay F, Falco P, Crippa C, Montefusco V, Patriarca F, Rossini F, Caltagirone S, Benevolo G, Pescosta N, Guglielmelli T, Bringhen S, Offidani M, Giuliani N, Petrucci MT, Musto P, Liberati AM, Rossi G, Corradini P, Boccadoro M.

J Clin Oncol. 2010 Feb 10;28(5):800-7. doi: 10.1200/JCO.2009.22.7561. Epub 2010 Jan 4. Erratum in: J Clin Oncol. 2010 May 1;28(13):2314.

PMID:
20048187
[PubMed - indexed for MEDLINE]
Free Article
11.

Bortezomib-thalidomide-based regimens improved clinical outcomes without increasing toxicity as induction treatment for untreated multiple myeloma: a meta-analysis of phase III randomized controlled trials.

Huang H, Zhou L, Peng L, Fu W, Zhang C, Hou J.

Leuk Res. 2014 Sep;38(9):1048-54. doi: 10.1016/j.leukres.2014.06.009. Epub 2014 Jun 30.

PMID:
25052306
[PubMed - indexed for MEDLINE]
12.

How to maintain patients on long-term therapy: understanding the profile and kinetics of adverse events.

Mateos MV.

Leuk Res. 2012 Nov;36 Suppl 1:S35-43. doi: 10.1016/S0145-2126(12)70007-3. Review.

PMID:
23176723
[PubMed - indexed for MEDLINE]
13.

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.

Palumbo A, Bringhen S, Larocca A, Rossi D, Di Raimondo F, Magarotto V, Patriarca F, Levi A, Benevolo G, Vincelli ID, Grasso M, Franceschini L, Gottardi D, Zambello R, Montefusco V, Falcone AP, Omedé P, Marasca R, Morabito F, Mina R, Guglielmelli T, Nozzoli C, Passera R, Gaidano G, Offidani M, Ria R, Petrucci MT, Musto P, Boccadoro M, Cavo M.

J Clin Oncol. 2014 Mar 1;32(7):634-40. doi: 10.1200/JCO.2013.52.0023. Epub 2014 Jan 21.

PMID:
24449241
[PubMed - indexed for MEDLINE]
14.

An update on drug combinations for treatment of myeloma.

Srikanth M, Davies FE, Morgan GJ.

Expert Opin Investig Drugs. 2008 Jan;17(1):1-12. Review.

PMID:
18095914
[PubMed - indexed for MEDLINE]
15.

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial.

Palumbo A, Bringhen S, Rossi D, Cavalli M, Larocca A, Ria R, Offidani M, Patriarca F, Nozzoli C, Guglielmelli T, Benevolo G, Callea V, Baldini L, Morabito F, Grasso M, Leonardi G, Rizzo M, Falcone AP, Gottardi D, Montefusco V, Musto P, Petrucci MT, Ciccone G, Boccadoro M.

J Clin Oncol. 2010 Dec 1;28(34):5101-9. doi: 10.1200/JCO.2010.29.8216. Epub 2010 Oct 12.

PMID:
20940200
[PubMed - indexed for MEDLINE]
Free Article
16.
17.

Novel agents in the frontline management of multiple myeloma.

Loong HH.

Hematol Oncol Stem Cell Ther. 2008 Oct-Dec;1(4):201-9. Review.

PMID:
20058474
[PubMed - indexed for MEDLINE]
18.

Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance.

Usmani SZ, Sexton R, Hoering A, Heuck CJ, Nair B, Waheed S, Al Sayed Y, Chauhan N, Ahmad N, Atrash S, Petty N, van Rhee F, Crowley J, Barlogie B.

Blood. 2012 Aug 23;120(8):1597-600. doi: 10.1182/blood-2012-04-421883. Epub 2012 Jun 6.

PMID:
22674807
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Firstline treatment and maintenance in newly diagnosed multiple myeloma patients.

Roussel M, Facon T, Moreau P, Harousseau JL, Attal M.

Recent Results Cancer Res. 2011;183:189-206. doi: 10.1007/978-3-540-85772-3_9. Review.

PMID:
21509686
[PubMed - indexed for MEDLINE]
20.

Sequential bortezomib, dexamethasone, and thalidomide maintenance therapy after single autologous peripheral stem cell transplantation in patients with multiple myeloma.

Sahebi F, Frankel PH, Farol L, Krishnan AY, Cai JL, Somlo G, Thomas SH, Reburiano E, Popplewell LL, Parker PM, Spielberger RT, Kogut NM, Karanes C, Htut M, Ruel C, Duarte L, Murata-Collins JL, Forman SJ.

Biol Blood Marrow Transplant. 2012 Mar;18(3):486-92. doi: 10.1016/j.bbmt.2011.12.580. Epub 2011 Dec 22.

PMID:
22198542
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk